Back to results
US 2022/0031692 A1Published application
Buprenorphine dosing regimens
AssigneeIndivior UK Limited
InventorsAzmi NASSER, Celine M. LAFFONT, Christian A. HEIDBREDER
Life of this patent
Estimating the term…
Abstract
The disclosure provides a dosage regimen using sustained-release buprenorphine formulations to produce therapeutic levels of buprenorphine in patients for the treatment of pain or opioid use disorders.
Claims24
1-67. (canceled)
A method of treating opioid use disorder in a human in need thereof, the method comprising the steps of:
- (a) administering a first composition comprising about 280 mg to 320 mg of buprenorphine to the human once per month by subcutaneous injection for two months;
- wherein the first composition comprises (i) about 18 wt % of buprenorphine free base;
- (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer;
- and (iii) about 50 wt % of N-methyl-2-pyrrolidone;
- and
- (b) administering a second composition comprising about 80 mg to 120 mg of buprenorphine to the human once per month by subcutaneous injection beginning with a third month;
- wherein the second composition comprises (i) about 18 wt % of buprenorphine free base;
- (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer;
- and (iii) about 50 wt % of N-methyl-2-pyrrolidone;
- to treat the opioid use disorder.
7 more elements
A method of treating opioid use disorder in a human in need thereof, the method comprising the steps of:
- (a) administering a first composition comprising about 280 mg to 320 mg of buprenorphine or a pharmaceutically acceptable salt thereof to the human once per month by injection for two months;
- and
- (b) administering a second composition comprising about 80 mg to 120 mg of buprenorphine or a pharmaceutically acceptable salt thereof to the human once per month by injection beginning with a third month;
- to treat the opioid use disorder.
1 more element
A method of treating opioid addiction in a human in need thereof, the method comprising the steps of:
- (a) transmucosally administering a composition comprising buprenorphine;
- (b) subcutaneously administering a first composition comprising about 280 mg to 320 mg of buprenorphine once per month for two months;
- wherein the first composition comprises (i) about 18 wt % of buprenorphine free base;
- (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer;
- and (iii) about 50 wt % of N-methyl-2-pyrrolidone;
- and
- (c) subcutaneously administering a second composition comprising about 80 mg to 120 mg of buprenorphine once per month beginning with a third month;
- wherein the second composition comprises (i) about 18 wt % of buprenorphine free base;
- (ii) about 32 wt % of a poly(DL-lactide-co-glycolide) copolymer;
- and (iii) about 50 wt % of N-methyl-2-pyrrolidone.
7 more elements
Dependencies are inferred from the claim text.